SG11201809172WA - Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide - Google Patents
Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamideInfo
- Publication number
- SG11201809172WA SG11201809172WA SG11201809172WA SG11201809172WA SG11201809172WA SG 11201809172W A SG11201809172W A SG 11201809172WA SG 11201809172W A SG11201809172W A SG 11201809172WA SG 11201809172W A SG11201809172W A SG 11201809172WA SG 11201809172W A SG11201809172W A SG 11201809172WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- hydroxypropan
- methylbutyl
- carboxamide
- hydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16167649 | 2016-04-29 | ||
| EP16167650 | 2016-04-29 | ||
| PCT/EP2017/059764 WO2017186700A1 (en) | 2016-04-29 | 2017-04-25 | Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809172WA true SG11201809172WA (en) | 2018-11-29 |
Family
ID=58579196
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808686VA SG11201808686VA (en) | 2016-04-29 | 2017-04-25 | Synthesis of indazoles |
| SG11201809172WA SG11201809172WA (en) | 2016-04-29 | 2017-04-25 | Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808686VA SG11201808686VA (en) | 2016-04-29 | 2017-04-25 | Synthesis of indazoles |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US10633365B2 (zh) |
| EP (2) | EP3448849B1 (zh) |
| JP (2) | JP6821701B2 (zh) |
| KR (2) | KR102379948B1 (zh) |
| CN (4) | CN112898269A (zh) |
| AU (2) | AU2017256659B2 (zh) |
| BR (1) | BR112018072247A2 (zh) |
| CA (2) | CA3022327A1 (zh) |
| CL (2) | CL2018003085A1 (zh) |
| CO (2) | CO2018011607A2 (zh) |
| CU (1) | CU24593B1 (zh) |
| DK (1) | DK3448849T3 (zh) |
| DO (1) | DOP2018000236A (zh) |
| EA (1) | EA038103B1 (zh) |
| EC (1) | ECSP18081451A (zh) |
| ES (1) | ES2801800T3 (zh) |
| GE (1) | GEP20217230B (zh) |
| HU (1) | HUE049331T2 (zh) |
| IL (2) | IL262391B (zh) |
| JO (2) | JOP20170101B1 (zh) |
| LT (1) | LT3448849T (zh) |
| MA (1) | MA44758A (zh) |
| MX (2) | MX2018013227A (zh) |
| NI (1) | NI201800111A (zh) |
| PE (2) | PE20240651A1 (zh) |
| PH (1) | PH12018502288A1 (zh) |
| PL (1) | PL3448849T3 (zh) |
| PT (1) | PT3448849T (zh) |
| RS (1) | RS60419B1 (zh) |
| SG (2) | SG11201808686VA (zh) |
| SI (1) | SI3448849T1 (zh) |
| SV (1) | SV2018005776A (zh) |
| TN (1) | TN2018000359A1 (zh) |
| TW (3) | TWI671291B (zh) |
| UA (2) | UA123550C2 (zh) |
| UY (2) | UY37214A (zh) |
| WO (2) | WO2017186693A1 (zh) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| CN109153665B (zh) | 2016-03-03 | 2021-10-15 | 拜耳医药股份有限公司 | 新的2-取代的吲唑、其制备方法、包含其的药物制剂及其用于制备药物的用途 |
| DK3448849T3 (da) | 2016-04-29 | 2020-06-29 | Bayer Pharma AG | Syntese af indazoler |
| LT3448848T (lt) | 2016-04-29 | 2023-11-27 | Bayer Pharma Aktiengesellschaft | Polimorfinė n-{6-(2-hidroksipropan-2-il)-2-[2-(metilsulfonil)etil]-2h-indazol-5-il}-6-(trifluormetil)piridin-2-karboksamido forma |
| WO2017207481A1 (en) * | 2016-06-01 | 2017-12-07 | Bayer Animal Health Gmbh | Substituted indazoles ueful for treatment and prevention of allergic and/or inflammatory diseases in animals |
| EA201892790A1 (ru) | 2016-06-01 | 2019-06-28 | Байер Фарма Акциенгезельшафт | Применение 2-замещенных индазолов для лечения и профилактики аутоиммунных заболеваний |
| BR112020026507A8 (pt) | 2018-06-25 | 2023-01-31 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Composto de isotiazolo[5,4-d]pirimidinas como inibidor de irak4 |
| KR102392788B1 (ko) | 2019-01-08 | 2022-04-28 | 주식회사 엘지에너지솔루션 | 폴더블 사이드 플레이트를 구비하는 배터리 모듈 및 그 제조 방법 |
| CN111499612B (zh) * | 2019-01-30 | 2022-12-30 | 上海美悦生物科技发展有限公司 | 一种作为irak抑制剂的化合物及其制备方法和用途 |
| CN113521079A (zh) * | 2020-04-20 | 2021-10-22 | 上海领泰生物医药科技有限公司 | Irak4抑制剂在治疗ali/ards中的应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7163937B2 (en) | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| US20100048660A1 (en) | 2006-02-10 | 2010-02-25 | Graham Michael Wynne | Treatment of duchenne muscular dystrophy |
| WO2008001883A1 (fr) | 2006-06-29 | 2008-01-03 | Nissan Chemical Industries, Ltd. | DÉRIVÉ D'ACIDE α-AMINÉ ET PRODUIT PHARMACEUTIQUE QUI LE COMPREND EN TANT QUE MATIÈRE ACTIVE |
| AU2007292929A1 (en) | 2006-09-07 | 2008-03-13 | Biogen Idec Ma Inc. | Indazole derivatives as modulators of interleukin- 1 receptor-associated kinase |
| WO2011043479A1 (ja) | 2009-10-09 | 2011-04-14 | 田辺三菱製薬株式会社 | 脳梗塞治療薬 |
| WO2011153588A1 (en) | 2010-06-10 | 2011-12-15 | Biota Scientific Management Pty Ltd | Viral polymerase inhibitors |
| WO2012084704A1 (en) | 2010-12-20 | 2012-06-28 | Merck Serono S.A. | Indazolyl triazole derivatives as irak inhibitors |
| WO2013106254A1 (en) | 2012-01-11 | 2013-07-18 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
| JP6283862B2 (ja) * | 2012-12-07 | 2018-02-28 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規インダニルオキシジヒドロベンゾフラニル酢酸 |
| US9126984B2 (en) * | 2013-11-08 | 2015-09-08 | Iteos Therapeutics | 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| SG11201605408RA (en) * | 2014-01-10 | 2016-07-28 | Aurigene Discovery Tech Ltd | Indazole compounds as irak4 inhibitors |
| JO3705B1 (ar) * | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| JP6847855B2 (ja) * | 2015-04-30 | 2021-03-24 | バイエル ファーマ アクチエンゲゼルシャフト | Ｉｒａｋ４の阻害剤とｂｔｋの阻害剤の組み合わせ |
| BR112018000624A2 (pt) | 2015-07-15 | 2018-09-18 | Aurigene Discovery Technologies Limited | compostos de indazol e azaindazol como inibidores de irak-4 |
| CN109153665B (zh) | 2016-03-03 | 2021-10-15 | 拜耳医药股份有限公司 | 新的2-取代的吲唑、其制备方法、包含其的药物制剂及其用于制备药物的用途 |
| EP3219329A1 (en) * | 2016-03-17 | 2017-09-20 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib |
| DK3448849T3 (da) | 2016-04-29 | 2020-06-29 | Bayer Pharma AG | Syntese af indazoler |
| LT3448848T (lt) | 2016-04-29 | 2023-11-27 | Bayer Pharma Aktiengesellschaft | Polimorfinė n-{6-(2-hidroksipropan-2-il)-2-[2-(metilsulfonil)etil]-2h-indazol-5-il}-6-(trifluormetil)piridin-2-karboksamido forma |
| EA201892790A1 (ru) | 2016-06-01 | 2019-06-28 | Байер Фарма Акциенгезельшафт | Применение 2-замещенных индазолов для лечения и профилактики аутоиммунных заболеваний |
| WO2017207481A1 (en) | 2016-06-01 | 2017-12-07 | Bayer Animal Health Gmbh | Substituted indazoles ueful for treatment and prevention of allergic and/or inflammatory diseases in animals |
-
2017
- 2017-04-25 DK DK17719256.4T patent/DK3448849T3/da active
- 2017-04-25 CN CN202110078561.3A patent/CN112898269A/zh active Pending
- 2017-04-25 GE GEAP201714932A patent/GEP20217230B/en unknown
- 2017-04-25 KR KR1020187030703A patent/KR102379948B1/ko active IP Right Grant
- 2017-04-25 EP EP17719256.4A patent/EP3448849B1/en active Active
- 2017-04-25 MX MX2018013227A patent/MX2018013227A/es unknown
- 2017-04-25 JP JP2018556410A patent/JP6821701B2/ja active Active
- 2017-04-25 WO PCT/EP2017/059748 patent/WO2017186693A1/en active Application Filing
- 2017-04-25 EA EA201892407A patent/EA038103B1/ru unknown
- 2017-04-25 MA MA044758A patent/MA44758A/fr unknown
- 2017-04-25 SI SI201730292T patent/SI3448849T1/sl unknown
- 2017-04-25 PT PT177192564T patent/PT3448849T/pt unknown
- 2017-04-25 CA CA3022327A patent/CA3022327A1/en active Pending
- 2017-04-25 AU AU2017256659A patent/AU2017256659B2/en active Active
- 2017-04-25 AU AU2017257208A patent/AU2017257208B2/en active Active
- 2017-04-25 CN CN201780040907.2A patent/CN109415339A/zh active Pending
- 2017-04-25 SG SG11201808686VA patent/SG11201808686VA/en unknown
- 2017-04-25 KR KR1020187030702A patent/KR102409105B1/ko active IP Right Grant
- 2017-04-25 LT LTEP17719256.4T patent/LT3448849T/lt unknown
- 2017-04-25 ES ES17719256T patent/ES2801800T3/es active Active
- 2017-04-25 BR BR112018072247-2A patent/BR112018072247A2/pt active Search and Examination
- 2017-04-25 CN CN201780026606.4A patent/CN109071491B/zh active Active
- 2017-04-25 UA UAA201811327A patent/UA123550C2/uk unknown
- 2017-04-25 JP JP2018556406A patent/JP6916207B2/ja active Active
- 2017-04-25 CA CA3022329A patent/CA3022329A1/en active Pending
- 2017-04-25 TN TNP/2018/000359A patent/TN2018000359A1/en unknown
- 2017-04-25 HU HUE17719256A patent/HUE049331T2/hu unknown
- 2017-04-25 RS RS20200749A patent/RS60419B1/sr unknown
- 2017-04-25 WO PCT/EP2017/059764 patent/WO2017186700A1/en active Application Filing
- 2017-04-25 PE PE2023003161A patent/PE20240651A1/es unknown
- 2017-04-25 PE PE2018002240A patent/PE20190172A1/es unknown
- 2017-04-25 EP EP17718559.2A patent/EP3448847A1/en active Pending
- 2017-04-25 CN CN202410286070.1A patent/CN118184628A/zh active Pending
- 2017-04-25 US US16/097,463 patent/US10633365B2/en active Active
- 2017-04-25 MX MX2018013232A patent/MX2018013232A/es unknown
- 2017-04-25 US US16/097,506 patent/US10501437B2/en active Active
- 2017-04-25 PL PL17719256T patent/PL3448849T3/pl unknown
- 2017-04-25 CU CU2018000130A patent/CU24593B1/es unknown
- 2017-04-25 SG SG11201809172WA patent/SG11201809172WA/en unknown
- 2017-04-25 UA UAA201811328A patent/UA122882C2/uk unknown
- 2017-04-27 JO JOP/2017/0101A patent/JOP20170101B1/ar active
- 2017-04-27 JO JOP/2017/0102A patent/JOP20170102B1/ar active
- 2017-04-28 UY UY0001037214A patent/UY37214A/es not_active Application Discontinuation
- 2017-04-28 UY UY0001037217A patent/UY37217A/es active IP Right Grant
- 2017-04-28 TW TW106114179A patent/TWI671291B/zh active
- 2017-04-28 TW TW108120349A patent/TW201936599A/zh unknown
- 2017-04-28 TW TW106114181A patent/TWI651316B/zh active
-
2018
- 2018-10-15 IL IL262391A patent/IL262391B/en unknown
- 2018-10-16 IL IL262413A patent/IL262413B/en active IP Right Grant
- 2018-10-26 PH PH12018502288A patent/PH12018502288A1/en unknown
- 2018-10-29 DO DO2018000236A patent/DOP2018000236A/es unknown
- 2018-10-29 CO CONC2018/0011607A patent/CO2018011607A2/es unknown
- 2018-10-29 NI NI201800111A patent/NI201800111A/es unknown
- 2018-10-29 CL CL2018003085A patent/CL2018003085A1/es unknown
- 2018-10-29 EC ECSENADI201881451A patent/ECSP18081451A/es unknown
- 2018-10-29 CL CL2018003097A patent/CL2018003097A1/es unknown
- 2018-10-29 CO CONC2018/0011655A patent/CO2018011655A2/es unknown
- 2018-10-29 SV SV2018005776A patent/SV2018005776A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809172WA (en) | Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201809132RA (en) | Novel compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201809126RA (en) | Aromatic sulfonamide derivatives | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201807913XA (en) | Stabilized soluble pre-fusion rsv f proteins | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201907435PA (en) | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | |
| SG11201804587QA (en) | Isoindole compounds | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201810078PA (en) | Stabilized pre-fusion rsv f proteins | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors |